🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Stoke-on-Trent
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Stoke-on-Trent, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2853 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 25 Sep 2026, 03:15 UTC
2853
Studies in scope
industry-sponsored, all four open statuses
1387
Recruiting now
open to new participants
544
Lead sponsors
across recruiting studies
Top sites
London 2012 Manchester 669 Birmingham 470 Glasgow 439 Cambridge 418
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Novartis Pharmaceuticals3 Takeda3 Janssen Research & Development, LLC3 Ascletis Pharma (China) Co., Limited2 GlaxoSmithKline2
Site city
London2012 Manchester669 Birmingham470 Glasgow439 Cambridge418
All 425 cities
Target enrolment
to

Trials with a site in Stoke-on-Trent

42 of 2853 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT07743463Obesity, Overweight, Chronic Weight Management
DrugASC30 A1
Ascletis Pharma (China) Co., Limited
Phase 3
3,003
Bellshill, Cardiff, Edgbaston, London, Manchester, Stoke-on-Trent, Warrington
2026-08-31
Recruiting
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT07743450Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus
DrugASC30 A1
Ascletis Pharma (China) Co., Limited
Phase 3
1,560
Cardiff, Edgbaston, Glasgow, London, Manchester, Stoke-on-Trent, Warrington
2026-08-28
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496Lupus Erythematosus, Systemic
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
600
Bath, Cambridge, Greater London, Newcastle upon Tyne, Peterborough, Reading, Southampton, Stoke-on-Trent
2026-03-05
Recruiting
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
NCT07322003Amyotrophic Lateral Sclerosis
DrugPridopidine
Prilenia
Phase 3
500
London, Stoke-on-Trent
2026-02-01
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146Small-cell Lung Cancer
DrugZL-1310
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Cambridge, London, Chelsea, Sutton, Stoke-on-Trent, Nottingham, Wolverhampton
2025-11-30
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
NCT07291037Non-small Cell Lung Cancer (NSCLC)
DrugsDatopotamab deruxtecan·Dato-DXd·Paclitaxel
AstraZeneca
Phase 3
400
Huddersfield, London, Maidstone, Norwich, Stoke-on-Trent
2025-10-31
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593Peripheral Arterial Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
1,205
London, Plymouth, Stoke-on-Trent, Swansea, West End
2025-10-31
Recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
NCT07018700Episodic Migraine
DrugXeomin
Merz Therapeutics GmbH
Phase 3
990
Stoke-on-Trent
2025-08-21
Recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
NCT07018713Chronic Migraine
DrugXeomin
Merz Therapeutics GmbH
Phase 3
780
Stoke-on-Trent
2025-08-21
Recruiting
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318Immune Thrombocytopenic Purpura (ITP)
DrugMezagitamab
Takeda
Phase 3
150
Leicester, Southampton, Southwark, Liverpool, Glasgow, Stoke-on-Trent, Leeds, London
2025-08-14
Recruiting
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
NCT05691244Acute Ischemic Stroke, Cerebral Stroke
DrugSovateltide
Pharmazz, Inc.
Phase 3
514
Bury, London, Southampton, Wolverhampton, Harrow, Newcastle, Stoke-on-Trent
2025-07-24
Recruiting
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
NCT06990867Acute Ischemic Stroke
Corxel Pharmaceuticals
Phase 2/3
740
London, Stoke-on-Trent
2025-05-15
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
DrugFelzartamab
Biogen
Phase 3
454
London, Preston, Leicester, Sheffield, Stoke-on-Trent
2025-05-08
Recruiting
OrthoPureXT Multiligament PMCF Study
NCT05655156Multiligament Knee Injuries
Tissue Regenix Ltd
Not applicable
28
Stoke-on-Trent
2025-04
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
600
London, Coventry, Bradford, Harlow, Oxford, Stoke-on-Trent, Wolverhampton
2025-03-10
Recruiting
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06722235Immune Thrombocytopenic Purpura (ITP)
DrugMezagitamab
Takeda
Phase 3
171
Leicester, Southampton, Southwark, Liverpool, Glasgow, Stoke-on-Trent, Leeds, London
2025-02-27
Active, closed
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
NCT06843239Systemic Sclerosis (SSc), Scleroderma
Zura Bio Inc
Phase 2
80
Aberdeen, Bath, Dundee, Leeds, Liverpool, London, Stoke-on-Trent
2025-02-06
Active, closed
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
NCT06543914Migraine
AbbVie
Observational
1,314
Hull, Edinburgh, London, Nottingham, Stoke-on-Trent, Leeds, Swindon, Worcester
2024-11-26
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
196
Sheffield, Stoke-on-Trent
2024-10-29
Active, closed
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
NCT06643481Amyotrophic Lateral Sclerosis (ALS)
DrugVHB937
Novartis Pharmaceuticals
Phase 2
251
Sheffield, Farnborough, London, Stoke-on-Trent
2024-10-17
Recruiting
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566CLL/SLL
DrugLisaftoclax
Ascentage Pharma Group Inc.
Phase 3
400
Birmingham, Bournemouth, Liverpool, London, Manchester, Stoke-on-Trent, Swansea, West Bromwich
2023-12-20
Recruiting
Post-Market Clinical Follow Up Study With Navitor Valve
NCT06008080Aortic Stenosis
Abbott Medical Devices
Observational
1,000
London, Middlesbrough, Stoke-on-Trent, Wolverhampton
2023-09-29
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589Asthma
DrugTezepelumab
AstraZeneca
Phase 3
231
Birmingham, Bradford, Bristol, Glasgow, Leicester, London, Nottingham, Stoke-on-Trent
2023-08-24
Active, closed
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016Multiple Myeloma
DrugsIberdomide·Lenalidomide
Bristol-Myers Squibb
Phase 3
1,230
Aberdeen, Windsor, Derby, Bournemouth, Portsmouth, Stoke-on-Trent, Edinburgh, London
2023-06-22
Recruiting
Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.
NCT03994471End Stage Renal Disease
Iperboreal Pharma Srl
Phase 3
170
Birmingham, Bradford, Brighton, Canterbury, London, Oxford, Sheffield, Stoke-on-Trent
2022-12-14
Active, closed
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
NCT05407324Amyotrophic Lateral Sclerosis
Corcept Therapeutics
Phase 2
279
Stoke-on-Trent
2022-11-15
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020Multiple Myeloma
DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide
Pfizer
Phase 3
1,116
Leicester, Edinburgh, Oxford, Stoke-on-Trent, Cardiff, Glasgow
2022-11-10
Recruiting
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085Relapsed or Refractory Multiple Myeloma
DrugsMezigdomide·Bortezomib·Pomalidomide·Dexamethasone
Celgene
Phase 3
810
Cambridge, Truro, Airdrie, London, Leicester, Barnet, Newcastle upon Tyne, Stoke-on-Trent
2022-09-20
Active, closed
Post-market Clinical Follow-up (PMCF) Study of the Poly-Tape Devices for Medial Patellofemoral Ligament (MPFL) Reconstruction
NCT05264389Medial Patellofemoral Dislocation
Xiros Ltd
Observational
59
Great Yarmouth, Manchester, Stoke-on-Trent, Winchester, Yeovil
2022-09-05
Recruiting
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma
NCT05222529Asthma
Novartis Pharmaceuticals
Phase 2
42
London, Stoke-on-Trent
2022-08-29
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
DrugsGilteritinib·Azacitidine·Venetoclax
Sumitomo Pharma America, Inc.
Phase 1/2
606
Birmingham, Bristol, Edinburgh, London, Manchester, Oxford, Stoke-on-Trent, Sutton
2022-02-28
Recruiting
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT05065216Acute Stroke, Ischemic Stroke, Stroke
DiaMedica Therapeutics Inc
Phase 2/3
728
Exeter, Newcastle upon Tyne, Cambridge, London, Stoke-on-Trent, Kirkcaldy, Leeds, Middlesbrough
2021-11-07
Active, closed
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210Arthritis, Psoriatic
DrugGuselkumab
Janssen Research & Development, LLC
Phase 4
411
Barnet, Bradford, Coventry, Leeds, Manchester, Newcastle, Stoke-on-Trent
2021-08-30
Active, closed
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
NCT04908202Psoriatic Arthritis
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
670
Southampton, Harlow, Stoke-on-Trent
2021-07-13
Active, closed
The SELUTION DeNovo Study
NCT04859985Coronary Artery Disease
M.A. Med Alliance S.A.
Not applicable
3,326
Stoke-on-Trent, Bournemouth, Brighton, Bristol, Edinburgh, Glasgow, Leicester, Manchester
2021-05-15
Active, closed
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
NCT04527380Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
DrugsIxekizumab·Adalimumab
Eli Lilly and Company
Phase 3
101
Bristol, Liverpool, Nottingham, Oxford, Stoke-on-Trent, Sheffield
2021-04-13
Active, closed
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623Multiple Myeloma
DrugsBelantamab mafodotin·Bortezomib·Pomalidomide·Dexamethasone
GlaxoSmithKline
Phase 3
302
London, Plymouth, Southampton, Stoke-on-Trent, Sutton
2020-10-01
Active, closed
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04162210Multiple Myeloma
DrugsBelantamab mafodotin·Dexamethasone
GlaxoSmithKline
Phase 3
325
Airdrie, Dundee, Edinburgh, London, Nottingham, Oxford, Plymouth, Stoke-on-Trent
2020-04-02
Active, closed
Clinical Study of Bone Graft Substitutes in Orthopaedic and Spinal Applications.
NCT03570606Bone Deformity
Ceramisys Ltd
Observational
220
Doncaster, Birmingham, North Shields, Salford, Stoke-on-Trent, Taunton
2019-06-13
Active, closed
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
NCT03701334Early Breast Cancer
DrugRibociclib
Novartis Pharmaceuticals
Phase 3
5,101
Truro, Sutton, Cardiff, London, Nottingham, Oxford, Preston, Stoke-on-Trent
2018-12-07
Active, closed
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
NCT03539744Multiple Myeloma
DrugsPomalidomide·Venetoclax·Dexamethasone
AbbVie
Phase 3
265
Cambridge, London, Norwich, Nottingham, Glasgow, Stoke-on-Trent, Manchester, Portsmouth
2018-10-22
Recruiting
Neurovascular Product Surveillance Registry
NCT02988128Intracranial Aneurysm, Stroke, Ischemic
Medtronic Neurovascular Clinical Affairs
Observational
4,000
Birmingham, Edinburgh, London, Romford, Stoke-on-Trent
2016-12
Rows per page Showing 1–42 of 42
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-uk/city/stoke-on-trent

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,853 studies in total at the last sync on 25 Sep 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 42 of those studies with a site in Stoke-on-Trent.

How many clinical trials are recruiting in Stoke-on-Trent?

27 of the 42 studies on this page are recruiting new participants as of the 25 Sep 2026, 03:15 UTC sync. A further 0 have not yet opened recruitment, 15 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Stoke-on-Trent), 42 studies
PhaseStudiesRecruitingShare
Phase 3272064.3%
Observational5211.9%
Phase 2419.5%
Not applicable214.8%
Phase 2/3224.8%
Phase 1/2112.4%
Phase 4102.4%

Most active sponsors

Lead sponsors with the most studies (Stoke-on-Trent)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC32
Novartis Pharmaceuticals31
Takeda33
AbbVie20
Ascletis Pharma (China) Co., Limited22
AstraZeneca22
Bristol-Myers Squibb20
Eli Lilly and Company21
GlaxoSmithKline20
Merz Therapeutics GmbH22
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.